Vanguard Capital Management
IMDX

Vanguard Capital Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Vanguard Capital Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.34M Buy
735,847
+198,686
+37% +$981K ﹤0.01% 3174
2026
Q1 		$1.76M Buy
+537,161
New +$3.12M ﹤0.01% 3404

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management's IMDX Position: Q2 2026 in Review

Vanguard Capital Management increased its Insight Molecular Diagnostics (IMDX) stake by 37% in Q2 2026, buying an estimated $981K and bringing the position to 735,847 shares worth $4.34M. The position accounts for ﹤0.01% of the portfolio, ranked #3174.

Vanguard Capital Management first reported a position in IMDX in Q1 2026 and has held it in 2 quarters since. 39 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Vanguard Capital Management held 735,847 shares of Insight Molecular Diagnostics worth $4.34M as of Q2 2026.
  • Vanguard Capital Management bought 198,686 Insight Molecular Diagnostics shares in Q2 2026, an estimated $981K.
  • Insight Molecular Diagnostics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3174 holding.
  • Vanguard Capital Management first reported a position in Insight Molecular Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • 39 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.